What Nalagenetics does

Nalagenetics is a Singapore-based genomics company founded in 2016 that develops genetic testing products and clinical decision support software, with a particular specialization in Southeast Asian population-specific algorithms. The company operates a dual business model spanning direct-to-consumer DNA test kits sold through its own e-commerce platform and NalaCare clinic (RxMax covering 240+ medications, RxReady covering 180+ medications, MammoReady for breast cancer risk, CardiacReady for cardiovascular risk, NutriReady for nutrition, LifeReady for lifestyle, plus prenatal and rare disease diagnostics) and a B2B enterprise platform called Nala CDS that delivers NGS data analysis, pharmacogenomics reporting, polygenic risk scoring, and combined genetics-plus-epigenetics risk assessment to hospitals, laboratories, and research institutions on cloud-based or on-premise deployment.

The underlying technology stack combines multiple genomic modalities — microarray, qPCR, whole-genome sequencing (WGS), whole-exome sequencing (WES), and optical genome mapping (OGM) — with proprietary AI-powered bioinformatics for pharmacogenomics interpretation, polygenic risk scoring across 10+ conditions, and ACMG-compliant rare disease pipelines. The platform holds ISO 13485, ISO 27001, HIPAA, Singapore PDPA, and Indonesian PDP electronic-systems certifications, and integrates with national health infrastructure including Singapore's SingPass and PRECISE program and Indonesia's SatuSehat platform via HL7-based APIs.

The company monetizes through one-time test kit sales, recurring Nala CDS software licensing, professional services for healthcare partners, and the 3-month NalaCare wellness subscription. It is headquartered in Singapore (1093 Lower Delta Road) with a regional office in Jakarta (PT Nalagenetik Riset Indonesia), operates across at least 12 countries, and has strategic relationships with government genomics programs (BGSi/BB Binomika Indonesia Ministry of Health, Singapore PRECISE), academic and clinical partners (NUH, NUS), and technology collaborators (Basepair for Nala Basecamp, Revna Biosciences for African expansion). The company has raised approximately US$13.6 million to date, anchored by a US$12.6 million Series A in March 2022 co-led by Intudo Ventures and Vulcan Capital, and is led by co-founder and CEO Levana Sani alongside co-founders Alexander Lezhava, Astrid Irwanto (COO), and Jianjun Liu.

Name

Nalagenetics

Legal name

Nalagenetics Pte Ltd

Website

https://nalagenetics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Nalagenetics is a Singapore-based genomics company founded in 2016 that delivers population-specific genetic testing products (pharmacogenomics, cancer risk, cardiovascular risk, nutrition, lifestyle) and an AI-powered Nala Clinical Decision Support platform to individual consumers, hospitals, labs, and government genomics programs across 12 countries in Southeast Asia and beyond.

Ownership category

akta.pro rank

Product category

Genomics & Clinical Decision Support Software

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Medication Safety, Dosing & Drug Interaction CDS (HLACAGAB), Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

Keywords

• Genetic testing services
• Pharmacogenomics solutions
• Clinical decision support
• Precision medicine platforms
• Polygenic risk scoring

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Genetic Testing Products: One-time genetic testing services sold directly to consumers and healthcare providers. Products include pharmacogenomics tests (RxReady™, RxMax™), nutrigenetics (NutriReady™), lifestyle genomics (LifeReady™), cancer prevention (MammoReady™), and cardiovascular risk (CardiacReady™).
2. Clinical Decision Support Software Licensing: Nala CDS platform licensed to healthcare institutions, labs, and research organizations for genomic analysis and reporting. Includes cloud-based and on-premise deployment options.
3. Healthcare Provider Services: Professional services including training programs, sample collection logistics, genetic counseling, and clinical implementation support for healthcare partners.
4. NalaCare Wellness Program: 3-month personalized wellness programs combining genetic insights with clinical nutrition consultations, health analysis, and meal planning.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Nalagenetics sells clinical-grade DNA test kits spanning pharmacogenomics, hereditary and somatic cancer, prenatal, rare disease, cardiovascular, nutrition, and lifestyle assessments, analyzed through its patented Nala Clinical Decision Support (CDS) software platform. The Nala CDS platform is licensed separately to hospitals, laboratories, and research institutions for cloud or on-premise genomic analysis deployment, while consumers can purchase tests directly online or through the NalaCare Clinic.

Product overview

Nalagenetics is a genomics and precision medicine company offering a comprehensive portfolio of genetic testing products and a software platform for clinical decision support. The core offerings include pharmacogenomics tests (RxMax™ covering 240+ medications, RxReady™ covering 180+ medications), cancer risk prediction tests (MammoReady™ for breast cancer, Prevention of Cancer, Somatic Cancer Testing), cardiovascular risk assessment (CardiacReady™), nutrition and lifestyle genomics (NutriReady™, LifeReady™), prenatal testing, and rare disease diagnosis. These products are available as individual tests or bundled into health packages (Complete Wellness, Cardiovascular Prevention, Cancer Prevention, Medication Compatibility, Premarital Screening). The company also provides Nala CDS, an AI-powered clinical decision support platform for labs and researchers, and the Nala Personal Health Manager mobile app for patients to access their genetic reports. Products are designed specifically for Southeast Asian populations with localized algorithms and validation against diverse population data sets.

Differentiator

Problem solved

Functional benefit

Brands

• NalaCare Clinic: Healthcare clinic offering personalized counseling and preventive care services
• Nala Clinical Decision Support (CDS)
• Nala Personal Health Manager
• NalaCare Program
• Nala Basecamp
• NutriReady
• LifeReady
• CardiacReady
• MammoReady
• RxMax
• RxReady
• QuickSpit
• PGx Core

Products and services

• RxMax™ Pharmacogenomics test that analyzes a panel of 14 drug-gene pairs (including HLA-B*1502, HLA-B*5701, CYP2D6, CYP2C19, CYP2C9, SLCO1B1, VKORC1, DPYD, TPMT, UGT1A1, CYP3A5, CYP2B6, NUDT15, and CYP4F2) to provide personalized medication guidance for the top 100 most-prescribed drugs in Southeast Asia. Intended for consumers and clinicians concerned with drug response and adverse reactions.
• RxReady™ Pharmacogenomics DNA test covering 8 drug-gene pairs for the top 50 most-prescribed drugs in Southeast Asia, providing medication compatibility insights and a personalized lifetime medication response card. Targeted at consumers seeking streamlined pharmacogenomic guidance.
• MammoReady™ Genetic test assessing breast cancer risk via polygenic risk scoring combined with non-genetic risk factors. Designed for women seeking personalized breast cancer risk stratification to complement screening decisions.
• CardiacReady™ Genetic test providing cardiovascular disease risk assessment using polygenic risk scoring combined with clinical and epigenetic markers. Intended for consumers concerned with heart disease risk and prevention.
• NutriReady™ Nutrition-focused DNA test providing personalized dietary recommendations based on genetic predispositions. Targets consumers seeking genetically tailored nutrition guidance.
• LifeReady™ Lifestyle-focused DNA test covering predisposition to traits such as obesity, sleep patterns, and exercise response. Targeted at consumers interested in lifestyle optimization based on genetic profile.
• Prevention of Cancer (Hereditary Cancer Screening) Comprehensive hereditary cancer screening panel covering multiple cancer syndromes via microarray-based germline analysis. Designed for individuals with family history of cancer and clinicians managing high-risk patients.
• Somatic Cancer Testing Tumor profiling test using microarray and next-generation sequencing for somatic cancer variant detection and interpretation. Intended for oncologists and cancer patients seeking tumor-level genomic insights.
• Prenatal (NIPT) Non-invasive prenatal testing (NIPT) using next-generation sequencing to screen for fetal chromosomal abnormalities. Targeted at expectant parents and obstetricians.
• Rare Disease Diagnosis Whole exome and whole genome sequencing-based diagnostic service for rare disease identification using microarray, NGS, and Optical Genome Mapping technologies. Targeted at clinicians and families seeking diagnoses for suspected rare genetic conditions.
• Nala Clinical Decision Support (CDS) Platform Patented, AI-powered clinical decision support software platform for genomic analysis, available via cloud or on-premise deployment with HL7-based API integration to hospital information systems. Licensed to hospitals, clinics, and laboratories seeking clinical-grade genomic interpretation within routine care workflows.
• Nala Basecamp Next-generation sequencing analysis platform with one-click variant interpretation, distributed in partnership with Basepair for the global academic research community. Targeted at universities, research institutes, and biopharma R&D teams needing clinical-grade NGS tertiary analysis.
• Nala Personal Health Manager Mobile application available on iOS and Android for ordering genetic tests, accessing personal reports, and managing health insights on the go. Targeted at consumers who have purchased Nalagenetics tests.
• NalaCare Wellness Program 3-month structured wellness program that combines genetic testing with three consultations by in-house doctors and certified genetic counselors, plus weekly lifestyle coaching and tracking. Delivered through the NalaCare Clinic in Singapore for consumers seeking guided personalized wellness journeys.
• Healthcare Provider Clinical Services Clinical service offering for healthcare providers (specialists, physicians, genetic counselors) that combines genetic test ordering, sample logistics, result delivery, and patient report access through the Nalagenetics provider workflow. Targeted at clinical practitioners referring patients for genetic testing.

Quantifiable outcome

• Reduces serious side effects from medications by 30% when medications are matched to genetic profiles
• +7 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• Revna BiosciencescoreStrategic or Co-development Partner · 1 March 2026Partnership for DNA tests tailored to Africans. Revna Biosciences secured growth capital from Mirepa Capital to expand precision medicine capabilities, with active partnerships with AstraZeneca for biomarker testing and NalaGenetics for African-specific DNA tests.
• BasepaircoreStrategic or Co-development Partner · 1 October 2025Strategic collaboration to launch Nala Basecamp, a collaborative platform integrating clinical genomics with advanced data analysis for pharmacogenomics and polygenic risk scores. Leverages cloud-native, regulatory-compliant bioinformatics.
• National University Hospital (NUH)coreStrategic or Co-development PartnerPRECISE-CIP project collaboration for pharmacogenomics clinical implementation pilot. NUH serves as the clinical site for the pilot program with 1,500 patients using Nala CDS for personalized treatment decisions.
• National University of Singapore (NUS)coreStrategic or Co-development PartnerPRECISE-CIP project collaboration as part of Singapore's national precision medicine initiative. NUS provides research expertise and academic oversight for the pharmacogenomics clinical implementation pilot.
• Precision Health Research, Singapore (PRECISE)coreStrategic or Co-development PartnerSingapore's national precision medicine initiative driving Phase II of the National Precision Medicine programme. Coordinates clinical implementation pilots and partnerships with genomics companies including Illumina, Oxford Nanopore Technologies, and PacBio.
• BGSi (Biomedical and Genome Science Institute)flagshipStrategic or Co-development PartnerIndonesia's national precision medicine initiative led by BB Binomika of Ministry of Health. NalaGenetics provides pharmacogenomics bioinformatics pipeline for Indonesia's first 10K genomes project, deployed on AWS infrastructure with secure local data retention.
• BB Binomika - Ministry of Health IndonesiaflagshipStrategic or Co-development PartnerGovernment research institute leading Indonesia's genomic biobanking and precision medicine initiative. NalaGenetics supports the 10K genomes project with PGx analysis pipeline integrated with AWS genome data infrastructure.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Prenetics: Asia-headquartered (Hong Kong) genetic testing and precision health company offering both DTC consumer tests and clinical genomics; closest direct peer given overlapping Asia regional focus, PGx and preventive genetic testing, and hybrid B2C/B2B model.
• Color Health: Clinical genetics testing platform serving healthcare providers, employers and population health programs with hereditary cancer, PGx and polygenic risk tests; directly comparable CDS-enabled, B2B-leaning model.
• Invitae: Clinical genetic testing company offering comprehensive hereditary cancer, PGx and rare disease testing to healthcare providers with enterprise software integrations; comparable across the clinical genomics portfolio and B2B sales motion.
• Helix: Genomics platform powering population health and partner-branded DNA tests with a strong clinical decision support software layer; comparable operating model of platform-as-a-service + clinical reporting.
• Dante Labs: DTC whole genome and exome sequencing company with consumer-facing reports covering health, wellness and pharmacogenomics; comparable product breadth across NIPT, rare disease and prevention.

Broad incumbents

• 23andMe: Largest DTC consumer genetic testing brand with growing therapeutics and PGx efforts; broad incumbent in the same product category, competing especially for health-conscious consumer wallet share.
• MyHeritage: Consumer genetic testing company with health and ancestry products, expanding into clinical and wellness segments; broad incumbent competing in DTC genetic testing globally.
• Myriad Genetics: Established clinical genomics company with hereditary cancer (BRCA), PGx and prenatal testing; broad incumbent offering overlapping clinical genomics products to healthcare providers.

Emerging players

• Genomic Prediction: Polygenic risk score focused company (initially embryo screening, expanding into disease risk); emerging player with overlapping polygenic risk scoring technology applied to clinical genomics.
• Guardant Health: Oncology-focused genomics company offering liquid biopsy and molecular diagnostics; emerging player overlapping with Nala's somatic cancer testing and population-scale genomics infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC1xcqcX2QcNaOaKu7UFBwww
• LinkedInlinkedin.com/company/nalagenetics
• Instagraminstagram.com/nalagenetics
• Xx.com/nalagenetics
• Facebookfacebook.com/NalageneticsOfficial

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nalagenetics